About Daewoong Pharmaceutical
Daewoong Pharmaceutical is a company based in Seoul (South Korea) founded in 1945. The company has 1,750 employees as of December 31, 2024. Daewoong Pharmaceutical offers products and services including Daewoong Urusa, Impactamin Premium, Enblo, and Nabota. Daewoong Pharmaceutical operates in a competitive market with competitors including argenx, Abzena, MacroGenics, Patheon and Syngene, among others.
- Headquarter Seoul, South Korea
- Employees 1750 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Daewoong Pharmaceutical Co., Ltd.
-
Annual Revenue
$962.76 M (USD)3.44as on Dec 31, 2024
-
Net Profit
$16.77 M (USD)-79.68as on Dec 31, 2024
-
EBITDA
$131.11 M (USD)18.04as on Dec 31, 2024
-
Latest Funding Round
Not available
-
Investors
Not available
-
Employee Count
1750
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Daewoong Pharmaceutical
Daewoong Pharmaceutical is a publicly listed company on the KRX with ticker symbol 069620 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Daewoong Pharmaceutical
Daewoong Pharmaceutical offers a comprehensive portfolio of products and services, including Daewoong Urusa, Impactamin Premium, Enblo, and Nabota.
Capsule for liver fatigue recovery and health support
Vitamin B supplement with customized formulations
Oral medication for blood sugar management
Botulinum toxin for medical treatments
Funding Insights of Daewoong Pharmaceutical
Detailed funding history for Daewoong Pharmaceutical
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Daewoong Pharmaceutical
Investment portfolio details for Daewoong Pharmaceutical
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Daewoong Pharmaceutical
Detailed financials for Daewoong Pharmaceutical
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Daewoong Pharmaceutical Comparisons
Peer comparison for Daewoong Pharmaceutical
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Daewoong Pharmaceutical
Daewoong Pharmaceutical operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as argenx, Abzena, MacroGenics, Patheon and Syngene, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment.
|
|
| Locked | Locked | Locked |
Provider of antibody discovery, cell line development, and bio analytics services
|
|
| Locked | Locked | Locked |
A biopharmaceutical company focused on cancer therapeutics development.
|
|
| Locked | Locked | Locked |
Commercial manufacturing and pharmaceutical development services for biopharmaceutical industry
|
|
| Locked | Locked | Locked |
Provider of contract research and manufacturing services for both small molecules and biologics
|
|
| Locked | Locked | Locked |
Therapies for rare and devastating diseases are developed by Alexion.
|
Detailed competitors of Daewoong Pharmaceutical
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Daewoong Pharmaceutical
Complete news archive for Daewoong Pharmaceutical
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Daewoong Pharmaceutical
Daewoong Pharmaceutical was founded in 1945.
Daewoong Pharmaceutical is headquartered in Seoul, South Korea.
Seng-Ho Jeon is the current CEO of Daewoong Pharmaceutical.
As of Dec 31, 2024, the latest employee count at Daewoong Pharmaceutical is 1,750.
Annual revenue of Daewoong Pharmaceutical is $962.76M as on Dec 31, 2024.
Daewoong Pharmaceutical was founded in 1945 in Seoul, South Korea, and operates in the pharmaceutical sector. Therapies for gastrointestinal disorders, diabetes, fibrotic diseases, and autoimmune conditions are developed by the company, including depot injections, liquid suspensions, and biologics. Medical devices are also manufactured. The lead candidate, DWP 14012, is under Phase I trials for gastroesophageal reflux disease. Manufacturing facilities are certified under ISO14001 and OHSAS18001 standards.
Daewoong Pharmaceutical offers Daewoong Urusa, Impactamin Premium, Enblo, and Nabota.
Yes, Daewoong Pharmaceutical is publicly traded on KRX under the ticker symbol 069620.
The ticker symbol of Daewoong Pharmaceutical is 069620 on KRX.